Acalabrutinib interactions
Full monograph for AcalabrutinibCheck it against another medicine
Medicines
237 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Alteplase | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Apalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by… | 7 sources — open the full entry |
| Apixaban | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Aprepitant | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| Aspirin | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Aspirin + Dipyridamole | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.2 documented mechanisms | 3 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Betrixaban | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Bivalirudin | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Bromfenac Sodium | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Cabozantinib | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by… | 7 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by… | 4 sources — open the full entry |
| Cilostazol | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized…2 documented mechanisms | 4 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by… | 4 sources — open the full entry |
| Clopidogrel + Aspirin | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.2 documented mechanisms | 3 sources — open the full entry |
| Clopidogrel Bisulphate | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Crizotinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 1 sources — open the full entry |
| Dalteparin Sodium | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Dasatinib | Major | Synergy | Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 5 sources — open the full entry |
| Deferasirox | Major | Synergy | Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of… | 3 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Deucravacitinib | Major | Synergy | Coadministration of deucravacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Dexibuprofen | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Dexketoprofen | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Dexlansoprazole | Major | Absorption | Coadministration with proton pump inhibitors may significantly decrease the oral bioavailability of acalabrutinib and reduce its concentrations in plasma. The… | 2 sources — open the full entry |
| Dextran + Hypromellose | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Diclofenac Potassium | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Diclofenac Sodium | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Diclofenac Sodium + Misoprostol | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Diltiazem Hydrochloride | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| Dipyridamole | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Enoxaparin Sodium | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by… | 7 sources — open the full entry |
| Eptifibatide | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| ErythromycinLotionOral | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| EsomeprazolebaseMUPS preparation | Major | Absorption | Coadministration with proton pump inhibitors may significantly decrease the oral bioavailability of acalabrutinib and reduce its concentrations in plasma. The… | 2 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Absorption · Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by…2 documented mechanisms | 6 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Etodolac | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
Food & lifestyle
grapefruit juice
MajorMetabolism
Grapefruit juice may increase the plasma concentrations of acalabrutinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with grapefruit juice, but has been reported for other CYP450 3A4 inhibitors.
What to do: Acalabrutinib may be administered with or without food. Patients should avoid consumption of grapefruit and grapefruit juice during treatment with acalabrutinib.
1 source
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals (2017):
Conditions
Conditions in which Acalabrutinib needs care, as documented in this source.
Arrhythmias, Cardiac
ModerateAtrial fibrillation and atrial flutter have been observed in patients treated with acalabrutinib. It is recommended to monitor patients with abnormal heart rhythm for atrial fibrillation and atrial flutter and manage as clinically appropriate.
1 source
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals (2017):
Hemorrhage
ModerateSerious hemorrhagic events, including fatal events, have occurred in patients treated with acalabrutinib. Care should be exercised when using acalabrutinib in patients with bleeding disorders. It is recommended to monitor for signs of bleeding and to consider the benefit-risk of withholding therapy for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.
1 source
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals (2017):
Hepatic Insufficiency
ModerateAcalabrutinib is metabolized in the liver. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in subjects with mild or moderate hepatic impairment. The pharmacokinetic of acalabrutinib has not been evaluated in patients with severe hepatic impairment. Close monitoring of liver function is recommended in these patients.
1 source
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals (2017):
Infections
ModerateSerious infections (bacterial, viral or fungal), including fatal events and opportunistic infections have occurred in patients treated with acalabrutinib. Care should be exercised in patients at risk as in those at increased susceptibility to infection, such as neutropenic patients or those with a prior history of hepatitis B virus infection. It is recommended to monitor patients for signs and symptoms of infection and treat as medically appropriate. Consider prophylaxis in patients who are at increased risk for opportunistic infections.
1 source
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals (2017):
Kidney Diseases
ModerateAcalabrutinib undergoes minimal renal elimination. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild or moderate renal impairment. The pharmacokinetic of acalabrutinib has not been evaluated in patients with severe renal impairment or renal impairment requiring dialysis. Close monitoring of renal function is recommended in these patients.
1 source
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals (2017):